Q1 FY2027 EarningsQ1 FY27 beat consensus across top and bottom lines: revenue $339.4M vs. $327.9M expected, and adjusted EPS $1.14 vs. $1.08 expected. Both Plasma and Blood Management segments showed strong momentum, with organic revenue growing 5.9% YoY. Management raised FY27 revenue guidance to 5-8% (from 4-7%), while maintaining expansion targets for adjusted operating margin, signaling confidence in sustained procedural demand and portfolio transformation.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Heamonetics(HAE) the Revenue is 339.38 M (+5.6%), Beat estimate;the EBIT is 79.26 M (+2.2%), Beat estimate;the EPS is 0.72 (+2.86%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.34B5.60%
0.33B2.02%
+0.01B3.58%
EBITExceed expectations
0.08B2.20%
0.08B0.38%
+0.00B1.82%
EPSMiss expectations
0.722.86%
0.73334.76%
-0.01331.90%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf